Omeros reported $-47.96M in EBITDA for its fiscal quarter ending in September of 2023.





Ebitda Change Date
Adma Biologics USD 61.07M 12.52M Mar/2026
Alnylam Pharmaceuticals USD 245.34M 59.15M Jun/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Cytokinetics USD -169.32M 19.48M Mar/2026
Gilead Sciences USD 3.51B 489M Mar/2026
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Immunic USD -22.78M 753K Jun/2024
Insmed USD -148.3M 165.88M Mar/2026
Knight Therapeutics CAD 24.45M 3.46M Dec/2025
MacroGenics USD -30.2M 52.15M Mar/2026
Omeros USD -47.96M 7.39M Sep/2023
Pacira USD 48.67M 8.43M Jun/2026
Pfizer USD 6.01B 18M Jun/2026
Sarepta Therapeutics USD 375.48M 627.68M Mar/2026
United Therapeutics USD 355M 11.1M Jun/2026
Vertex Pharmaceuticals USD 1.33B 130.5M Jun/2026